FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns

FDA Panel Backs Wider Access To Six Peptide Therapies, Citing Grey Market Concerns Via American Greatness, A Food and Drug Administration (FDA) advisory panel has voted to recommend expanding legal access to six popular peptide compounds. Supporters say it could pull patients out of the unregulated grey market that has flourished under years of federal inaction. The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides during a two-day hearing in Maryland last week, weighing whether each should be added to the agency's Section 503A Bulks List. Reuters reported the panel voted in...